Intravenous (IV) Ibuprofen Market Size, Share, Industry Trends, Growth and Forecast 2023-2028

intravenous (IV) ibuprofen market,

According to the latest report by IMARC Group, titled “Intravenous (IV) Ibuprofen Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027,” offers a comprehensive analysis of the industry, which comprises insights on the global intravenous (IV) ibuprofen market share. The report also includes competitor and regional analysis, and contemporary advancements in the market.

The global intravenous (IV) ibuprofenmarket size reached US$ 6.3 Billion in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 10.2 Billion by 2028, exhibiting a growth rate (CAGR) of 7.78% during 2023-2028.

Ibuprofen is associated with the nonsteroidal anti-inflammatory drug (NSAID) class that is used to treat inflammation, pain, fever, etc. It inhibits cyclooxygenase COZ-1 and COX-2 enzymes that are required for the synthesis of prostaglandins (PG). Intravenous (IV) ibuprofen is utilized alone or with other medicines to relieve mild to severe discomfort. It is injected directly into the vein to block the production of certain natural substances that cause inflammation.Intravenous (IV) ibuprofen aids in reducing narcotic analgesic requirements and lower pain levels with an excellent safety profile. It also assists in improving pain control and minimizing the usage of opioid drugs in orthopedic and abdominal surgeries and fever.

Request And Get A Sample Brochure For Free:

Market Trends

The rising prevalence of arthritis, cardiovascular diseases (CVDs), cancer, etc., and the expanding geriatric population across countries, are among the key factors stimulating the intravenous (IV) ibuprofen market. Moreover, hectic working schedules and unhealthy lifestyles, as well as a consequent decline in physical activity and proper nutrition, have led to increasing incidences of chronic diseases, which is positively influencing the global market.

Besides this, the widespread adoption of intravenous (IV) ibuprofen to manage rheumatoid disorders, mild to moderate pain, fever, dysmenorrhea, osteoarthritis, etc., is acting as another significant growth-inducing factor. Furthermore, it is also used to treat mild fever, dental pain, gastrointestinal pain, ductus arteriosus in pediatrics, etc., which is propelling the market growth. Apart from this, continuous improvements in the healthcare infrastructures and the growing consumer health consciousness are expected to fuel the intravenous (IV) ibuprofen market over the forecasted period.

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market

Cumberland Pharmaceuticals Inc., Hyloris Pharmaceuticals SA, Recordati Rare Diseases Inc., VALMOR Laboratories CA and Xgen Pharmaceuticals Djb Inc.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Product Dose:

  • 100 Mg Dose
  • 200 Mg Dose
  • 400 Mg Dose
  • 800 Mg Dose 

Breakup by Indication:

  • Pain/Inflammatory
  • Fever 

Breakup by Age Group:

  • Pediatrics
  • Adults

Breakup by End-Use Sector:

  • Utility
  • Residential
  • Commercial and Industrial

Based on the end-use sector, the report finds that the utility sector dominates the market. There are many ongoing development projects undertaken by various nations, which require a continuous flow of electricity. Owing to this, there is a rising demand for power inverters in this sector.

Ask An Analyst:

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic, and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology, and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.

30 N Gould St Ste R

Sheridan, WY 82801 USA – Wyoming


Tel No:(D) +91 120 433 0800

Americas:- +1 631 791 1145 |

Africa and Europe :- +44-702-409-7331 |

Asia: +91-120-433-0800, +91-120-433-0800

%d bloggers like this: